• Gene fusion; HGNC; HGNC:3819; FOXO1 + HGNC; HGNC:8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (PubMed=17547718).
  

PubMed=17547718; DOI=10.1111/j.1749-0774.2007.00029.x
Ohi S.
Characterization, anticancer drug susceptibility and atRA-induced growth inhibition of a novel cell line (HUMEMS) established from pleural effusion of alveolar rhabdomyosarcoma of breast tissue.
Hum. Cell 20:39-51(2007)

PubMed=20712710; DOI=10.1111/j.1749-0774.2010.00086.x
Suzuki M., Tominaga N., Ide Y., Ohyama A., Nakahara T., Ishikawa H., Tanaka A., Mataga I.
Establishment and characterization of the rhabdomyosarcoma cell line designated NUTOS derived from the human tongue sarcoma: special reference to the susceptibility of anti-cancer drugs.
Hum. Cell 23:65-73(2010)

PubMed=23882450; DOI=10.3389/fonc.2013.00183; PMCID=PMC3713458
Hinson A.R.P., Jones R., Crose L.E.S., Belyea B.C., Barr F.G., Linardic C.M.
Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls.
Front. Oncol. 3:183.1-183.12(2013)

PubMed=23665679; DOI=10.1038/onc.2013.129
Sokolowski E., Turina C.B., Kikuchi K., Langenau D.M., Keller C.
Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma.
Oncogene 33:1877-1889(2014)